Press Releases
EndoGastric Solutions Announces Publication of Comparative Results for TIF Procedure vs. Traditional Anti-Reflux Surgery Techniques
TIF procedure patients experienced similar reduction in reflux symptom resolution with significantly reduced operative times compared to Nissen or Toupet fundoplication techniques SAN MATEO, Calif. (Sept 3, 2014)–EndoGastric Solutions® (EGS), a leader in endoluminal...
EndoGastric Solutions Announces Publication of Predictive Factors Associated with Successful Outcomes for the TIF® Procedure
Quality-of-Life Survey Scores on Medications and Presence of Esophagitis Appear to Be Best Correlated Predictors of Success SAN MATEO, Calif. (June 9, 2014)–EndoGastric Solutions® (EGS), a leader in endoluminal reconstructive treatment for gastroesophageal reflux...
EndoGastric Solutions Completes $30 million Financing Round
Financing to Support Clinical Publications, Reimbursement Initiatives and Research and Development SAN MATEO, Calif. (May 6, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced...
EndoGastric Solutions Announces 12-Month TEMPO Study Data Confirms TIF Procedure Dramatically Eliminates GERD Symptoms in Majority of Patients
Positive six-month results were maintained a year after TIF procedure; all control patients crossed over to receive TIF procedure and achieved similar results to original treatment group Data Presented at DDW® 2014 CHICAGO (May 5, 2014)—EndoGastric Solutions® (EGS), a...
EndoGastric Solutions Names Industry Veteran Skip Baldino CEO
Baldino brings nearly three decades of healthcare leadership experience to EGS as it works to advance the field of advanced endoluminal procedural techniques SAN MATEO, Calif. (May 1, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive...
EndoGastric Solutions Announces Publication of 6-Month Data from Randomized Controlled Trial Indicating TIF® Procedure’s Superior Reflux Symptom Control Compared to Proton Pump Inhibitor Therapy
Data Shows TIF Procedure Controls Subjective Parameters Better Than Maximum Dose PPI Therapy While Achieving Similar Objective Results SAN MATEO, Calif. (April 22, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for...
EndoGastric Solutions® Announces Strong Presence at Digestive Disease Week® 2014
Highlights include the presentation of 12-month follow-up data from first randomized controlled trial of Transoral Incisionless Fundoplication (TIF®) procedure with the EsophyX® device SAN MATEO, Calif. (April 28, 2014) EndoGastric Solutions® (EGS), the leader in...
EndoGastric Solutions Announces 12-Month Registry Data Show Durable Elimination of Troublesome Regurgitation and Heartburn for GERD Patients Who Underwent Transoral Incisionless Fundoplication (TIF®)
Results show 74% of patients were able to stop taking and remain off proton pump inhibitor medications at 12-month follow up SAN MATEO, Calif. (February 20, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for Gastroesophageal...
Corporate Statement Regarding Civil Settlement with the U.S. Department of Justice
SAN MATEO, Calif. (February 19, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease, announced today that it has reached a civil settlement with the U.S. Department of Justice related to...